DM2 mainly affects the muscles but can also impact other organs to a greater or lesser extent. It is very similar to another more common neuromuscular disease called myotonic dystrophy type 1 (DM1). Muscles decrease in volume, become weak (dystrophy) and have difficulty relaxing after they contract (myotonia).
DM2 is a “multisystem” disorder, meaning it affects several different organs (muscles, the heart, the digestive system, the nervous system, and, less frequently, the respiratory system). Symptoms usually start during adulthood and progress slowly, but this can vary greatly.
This document, published to coincide with the AFM-Téléthon General Meeting 2024, presents myotonic dystrophy type 2 research news from the past year (ongoing studies and clinical trials, scientific and medical publications, etc.).
Access the document Advances in myotonic dystrophy type 2 – June 2024
